India to Austria Pharmaceutical Export (2026) — $11.0M, 74 Suppliers | TransData Nexus

India to Austria Pharmaceutical Export (2026) — $11.0M, 74 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Austria

#	Formulation	Value	Share
1	Pyridoxine Hydrochloride 50mg Tablets (net Content : 46.4250 Pyridoxine Hydroch…	$2.3M	21.1%
2	Pharmaceutical Medicinal Products Glugon 1mg Injection Glucagon for Injection U…	$295.1K	2.7%
3	Injection Urokinase (hpfp - Urokinase 10	$242.8K	2.2%
4	Material No. - 995155 Rimactan 300mg 60h	$218.7K	2.0%
5	Other-esomeprazol+pharma 40mg Magensaftresistente Tabletten 30 Tablets (esomepr…	$205.6K	1.9%
6	Febuxostat 80mg Film Coated Tablets	$184.0K	1.7%
7	Material No. 995155 Rimactan 300mg60hgc Es	$166.8K	1.5%
8	Pharm Drug&med:pregabalin 100mg 9x10c(accord-at/de) Each Hard Gelatin Capsule C…	$115.7K	1.1%
9	Material No 996727 Rimactan Sdz 300mg60hgc Gb Batch No Pm8769 Mfg Date 11 04 20…	$113.1K	1.0%
10	Bleomycin for Injection USP 15 Units (5876 Vials)	$111.3K	1.0%
11	Material No. - 996727 Rimactan Sdz300mg 60hgc Gb	$107.7K	1.0%
12	Febuxostat 80mg Film Coated Tabletsnos	$100.5K	0.9%
13	Pharmaceutical Medicinal Products :-glugon B.no:glle4a5 Mfg.dt: 05/2024 Exp.dt:…	$100.0K	0.9%
14	Pharmaceutical Medicinal Products :-glugon B.no:glle4a3 Mfg.dt: 05/2024 Exp.dt:…	$100.0K	0.9%
15	Pharmaceutical Medicinal Products :-glugon B.no:glle4a4 Mfg.dt: 05/2024 Exp.dt:…	$100.0K	0.9%

India exports 19+ pharmaceutical formulations to Austria with a combined trade value of $11.0M. Key products include Febuxostat ($184K), Bleomycin ($111K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1,276 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Austria Trade Routes

1Febuxostat$184K

2Bleomycin$111K

These are the top pharmaceutical products exported from India to Austria, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Austria buyers, regulatory requirements, and logistics for that specific product corridor. Products include Febuxostat ($184K), Bleomycin ($111K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.

Top Indian Exporters to Austria

1Macleods Pharmaceuticals Ltd

$2.6M

2Sandoz Private Limited

$2.0M

3Intas Pharmaceuticals Limited

$1.4M

4Torrent Pharmaceuticals Ltd

$1.1M

5United Biotech Private Limited

Port Analysis — India to Austria Pharmaceutical Shipments

Indian Export Ports

BANGALORE AIR1.7%

SAHAR AIR CARGO ACC (INBOM4)12.4%

SAHAR AIR15.9%

NHAVA SHEVA SEA (INNSA1)4.5%

DELHI AIR7.4%

Austria Import Ports

VIENNA56.4%

Koper2.7%

Genoa6.3%

GENOA14.7%

LAKE NASH0.2%

Trade Statistics

Total Value$11.0M

Shipments1,276

Indian Exporters74

Austria Buyers109

Avg Shipment$9K

Products884

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B France

Last updated: March 28, 2026

Market Opportunity Assessment — Austria for Indian Pharma

Market size, healthcare system, growth outlook

1Market Size & Growth

Austria's pharmaceutical market is substantial, with revenues projected to reach approximately $3.82 billion in 2025, reflecting a 3.5% increase from the previous year. This growth trajectory is expected to continue, with a compound annual growth rate (CAGR) of 4.64% from 2025 to 2030, potentially reaching $4.79 billion by 2030. The market is characterized by a significant import dependency, with imports accounting for a substantial portion of the total pharmaceutical sales.

Generic drugs constitute a growing segment of the Austrian pharmaceutical market. Between 2024 and 2028, approximately 27% of the market's revenue is expected to be affected by patent expirations, presenting opportunities for generic drug manufacturers. However, the growth rate of generics in Austria is slower compared to other OECD countries, primarily due to a tightly managed reimbursement system that demands significant price reductions from both original and generic producers once patents expire. This results in minimal price differences between branded and generic pharmaceuticals, reducing the incentive for physicians and patients to switch to generics.

2Healthcare System

Austria's healthcare system is predominantly funded through statutory health insurance (SHI), covering over 99% of the population. (eurohealthobservatory.who.int) The SHI system is administered by multiple insurance funds, each with distinct fee and coverage structures. Health insurance is mandatory, with contributions based on income levels. The benefits package is comprehensive, encompassing a wide range of medical services. Out-of-pocket expenses, including co-payments for pharmaceuticals, are relatively low, with prescription charges capped annually to protect patients from excessive costs.

Competitive Landscape — India vs Other Pharmaceutical Suppliers to Austria

Competing origins, India's edge, challenges and threats

1Competing Origins

Austria's pharmaceutical market is supplied by a diverse array of sources, including domestic manufacturers, European Union (EU) producers, China, and other emerging markets. The EU, with its integrated market, plays a significant role in supplying pharmaceuticals to Austria. China has also been increasing its presence in the Austrian market, offering a range of pharmaceutical products. However, specific market share data for these regions is not readily available.

India's pharmaceutical exports to Austria have been growing steadily, with a total export value of $11.0 million USD over 1,276 shipments from 2022 to 2026. This indicates a consistent presence in the Austrian market, though precise market share figures are not specified.

2India's Competitive Edge

India's pharmaceutical industry offers several competitive advantages:

Cost Competitiveness: India is renowned for providing high-quality pharmaceuticals at affordable prices, making it an attractive source for cost-effective medicines.

Regulatory Compliance: India has the highest number of US FDA-approved plants outside the USA, demonstrating its adherence to stringent international quality standards.

Broad Portfolio: India's pharmaceutical exports encompass a wide range of products, including generics, active pharmaceutical ingredients (APIs), vaccines, biosimilars, and custom research manufacturing (CRM), catering to diverse therapeutic areas.

3Challenges & Threats

Despite its strengths, India's pharmaceutical exports to Austria face several challenges:

Regulatory Compliance: Navigating the complex regulatory landscape of the European Medicines Agency (EMA) and Austria's National Competent Authority requires meticulous attention to ensure compliance.

Competition from China: China's growing presence in the Austrian pharmaceutical market introduces additional competition, potentially affecting India's market share.

Quality Perception: Maintaining a strong reputation for quality is crucial, as any lapses can impact India's standing in the Austrian market.

Addressing these challenges is essential for India to strengthen its position in the Austrian pharmaceutical sector.

TransData Nexus Research · Global trade databasesMar 2026

FAQ — India to Austria Pharmaceutical Trade

What is the total value of India's pharmaceutical export to Austria?

India exported pharmaceuticals worth $11.0M to Austria across 1,276 verified shipments.

Who are the top Indian pharmaceutical exporters to Austria?

1. MACLEODS PHARMACEUTICALS LTD — $2.6M. 2. SANDOZ PRIVATE LIMITED — $2.0M. 3. INTAS PHARMACEUTICALS LIMITED — $1.4M. Total: 74 suppliers.

Which companies in Austria import pharmaceuticals from India?

1. AMEX EXPORT-IMPORT GMBH. — $2.3M. 2. GENERICON PHARMA GMBH — $1.2M. 3. TO THE ORDER — $1.0M. 109 buyers total.

What pharmaceutical products does India export most to Austria?

1. Pyridoxine Hydrochloride 50mg Tablets (net Content : 46.4250 Pyridoxine Hydroch… ($2.3M, 21.1%); 2. Pharmaceutical Medicinal Products Glugon 1mg Injection Glucagon for Injection U… ($295.1K, 2.7%); 3. Injection Urokinase (hpfp - Urokinase 10 ($242.8K, 2.2%); 4. Material No. - 995155 Rimactan 300mg 60h ($218.7K, 2.0%); 5. Other-esomeprazol+pharma 40mg Magensaftresistente Tabletten 30 Tablets (esomepr… ($205.6K, 1.9%)

Which ports handle pharmaceutical shipments from India to Austria?

Export: BANGALORE AIR, SAHAR AIR CARGO ACC (INBOM4), SAHAR AIR, NHAVA SHEVA SEA (INNSA1), DELHI AIR. Import: VIENNA, Koper, Genoa, GENOA, LAKE NASH.

Why does Austria import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $11.0M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Austria?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Austria pharmaceutical trade?

$8.6K per consignment across 1,276 shipments.

How many Indian pharmaceutical companies export to Austria?

74 Indian companies. Largest: MACLEODS PHARMACEUTICALS LTD with $2.6M.

How can I find verified Indian pharmaceutical suppliers for Austria?

TransData Nexus covers 74 active exporters with shipment history and trade values at transdatanexus.com.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Austria identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 1,276 verified shipments from 74 Indian exporters to 109 Austria buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

74 Exporters

109 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Austria Pharmaceutical Export